Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) was the recipient of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 63,600 shares, a drop of 38.8% from the December 15th total of 103,900 shares. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.2% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital reissued a “buy” rating and issued a $10.00 price objective on shares of Senti Biosciences in a research report on Monday, December 2nd.

Senti Biosciences Price Performance

NASDAQ SNTI traded down $0.09 on Tuesday, reaching $3.70. The company had a trading volume of 29,176 shares, compared to its average volume of 70,171. The firm has a market capitalization of $16.98 million, a PE ratio of -0.24 and a beta of 2.42. The firm has a 50-day moving average of $3.83 and a 200-day moving average of $2.99. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.